Atrial Fibrillation in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction

JACC: Heart Failure

Volumn 5, Issue 8, 2017, Pages 565-574

  Sartipy, Ulrik ^a,b   Dahlström, Ulf ^c   Fu, Michael ^d   Lund, Lars H ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c LINKÖPING UNIVERSITY   (Sweden)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

atrial fibrillation; heart failure; outcomes; phenotype; preserved ejection fraction; registry

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE; RENIN INHIBITOR;

AGE; AGED; ARTICLE; ATRIAL FIBRILLATION; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CLINICAL OUTCOME; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE REGISTRY; FEMALE; HEART FAILURE; HEART FAILURE WITH MID RANGE EJECTION FRACTION; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART FAILURE WITH REDUCED EJECTION FRACTION; HEART INFARCTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT INFORMATION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SEX; SINUS RHYTHM; SWEDEN; TRANSIENT ISCHEMIC ATTACK; ADULT; AGE DISTRIBUTION; COMPLICATION; EPIDEMIOLOGY; HEART STROKE VOLUME; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; PHYSIOLOGY; REGISTER; RISK FACTOR; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PREVALENCE; PROGNOSIS; REGISTRIES; RISK FACTORS; STROKE VOLUME; SWEDEN;

EID: 85023643875     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2017.05.001     Document Type: Article

References (35)

1. Ponikowski, P., Voors, A.A., Anker, S.D., et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 18 (2016), 891–975.
2. Kotecha, D., Piccini, J.P., Atrial fibrillation in heart failure: what should we do?. Eur Heart J 36 (2015), 3250–3257.
3. Steinberg, B.A., Zhao, X., Heidenreich, P.A., et al. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation 126 (2012), 65–75.
4. Stevenson, W.G., Stevenson, L.W., Middlekauff, H.R., et al. Improving survival for patients with atrial fibrillation and advanced heart failure. J Am Coll Cardiol 28 (1996), 1458–1463.
5. Maisel, W.H., Stevenson, L.W., Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol 91 (2003), 2D–8D.
6. Fonarow, G.C., Stough, W.G., Abraham, W.T., et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol 50 (2007), 768–777.
7. Yusuf, S., Pfeffer, M.A., Swedberg, K., et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362 (2003), 777–781.
8. Holmstrom, A., Sigurjonsdottir, R., Edner, M., Jonsson, A., Dahlstrom, U., Fu, M.L., Increased comorbidities in heart failure patients >/= 85 years but declined from >90 years: data from the Swedish Heart Failure Registry. Int J Cardiol 167 (2013), 2747–2752.
9. Lund, L.H., Donal, E., Oger, E., et al. Association between cardiovascular vs. non-cardiovascular co-morbidities and outcomes in heart failure with preserved ejection fraction. Eur J Heart Fail 16 (2014), 992–1001.
10. Kotecha, D., Chudasama, R., Lane, D.A., Kirchhof, P., Lip, G.Y., Atrial fibrillation and heart failure due to reduced versus preserved ejection fraction: A systematic review and meta-analysis of death and adverse outcomes. Int J Cardiol 203 (2016), 660–666.
11. Kotecha, D., Lam, C.S., Van Veldhuisen, D.J., Van Gelder, I.C., Voors, A.A., Rienstra, M., Heart failure with preserved ejection fraction and atrial fibrillation: vicious twins. J Am Coll Cardiol 68 (2016), 2217–2228.
12. Eapen, Z.J., Greiner, M.A., Fonarow, G.C., et al. Associations between atrial fibrillation and early outcomes of patients with heart failure and reduced or preserved ejection fraction. Am Heart J 167 (2014), 369–375.e2.
13. Santhanakrishnan, R., Wang, N., Larson, M.G., et al. Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction. Circulation 133 (2016), 484–492.
14. Olsson, L.G., Swedberg, K., Ducharme, A., et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol 47 (2006), 1997–2004.
15. Cheng, M., Lu, X., Huang, J., Zhang, J., Zhang, S., Gu, D., The prognostic significance of atrial fibrillation in heart failure with a preserved and reduced left ventricular function: insights from a meta-analysis. Eur J Heart Fail 16 (2014), 1317–1322.
16. Mamas, M.A., Caldwell, J.C., Chacko, S., Garratt, C.J., Fath-Ordoubadi, F., Neyses, L., A meta-analysis of the prognostic significance of atrial fibrillation in chronic heart failure. Eur J Heart Fail 11 (2009), 676–683.
17. McManus, D.D., Hsu, G., Sung, S.H., et al. Atrial fibrillation and outcomes in heart failure with preserved versus reduced left ventricular ejection fraction. J Am Heart Assoc, 2, 2013, e005694.
18. Banerjee, A., Taillandier, S., Olesen, J.B., et al. Ejection fraction and outcomes in patients with atrial fibrillation and heart failure: the Loire Valley Atrial Fibrillation Project. Eur J Heart Fail 14 (2012), 295–301.
19. Li, S.J., Sartipy, U., Lund, L.H., et al. Prognostic significance of resting heart rate and use of β-blockers in atrial fibrillation and sinus rhythm in patients with heart failure and reduced ejection fraction: findings from the Swedish Heart Failure Registry. Circ Heart Fail 8 (2015), 871–879.
20. Zakeri, R., Chamberlain, A.M., Roger, V.L., Redfield, M.M., Temporal relationship and prognostic significance of atrial fibrillation in heart failure patients with preserved ejection fraction: a community-based study. Circulation 128 (2013), 1085–1093.
21. Linssen, G.C., Rienstra, M., Jaarsma, T., et al. Clinical and prognostic effects of atrial fibrillation in heart failure patients with reduced and preserved left ventricular ejection fraction. Eur J Heart Fail 13 (2011), 1111–1120.
22. Jonsson, A., Edner, M., Alehagen, U., Dahlström, U., Heart failure registry: a valuable tool for improving the management of patients with heart failure. Eur J Heart Fail 12 (2010), 25–31.
23. Ludvigsson, J.F., Andersson, E., Ekbom, A., et al. External review and validation of the Swedish national inpatient register. BMC Public Health, 11, 2011, 450.
24. Ingelsson, E., Ärnlöv, J., Sundström, J., Lind, L., The validity of a diagnosis of heart failure in a hospital discharge register. Eur J Heart Fail 7 (2005), 787–791.
25. White, I.R., Royston, P., Wood, A.M., Multiple imputation using chained equations: Issues and guidance for practice. Stat Med 30 (2011), 377–399.
26. Triposkiadis, F., Giamouzis, G., Parissis, J., et al. Reframing the association and significance of co-morbidities in heart failure. Eur J Heart Fail 18 (2016), 744–758.
27. Maggioni, A.P., Anker, S.D., Dahlstrom, U., et al. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 15 (2013), 1173–1184.
28. Bjorck, S., Palaszewski, B., Friberg, L., Bergfeldt, L., Atrial fibrillation, stroke risk, and warfarin therapy revisited: a population-based study. Stroke 44 (2013), 3103–3108.
29. Lam, C.S., Lund, L.H., Microvascular endothelial dysfunction in heart failure with preserved ejection fraction. Heart 102 (2016), 257–259.
30. Owan, T.E., Hodge, D.O., Herges, R.M., Jacobsen, S.J., Roger, V.L., Redfield, M.M., Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355 (2006), 251–259.
31. Campbell, R.T., Jhund, P.S., Castagno, D., Hawkins, N.M., Petrie, M.C., McMurray, J.J., What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE?. J Am Coll Cardiol 60 (2012), 2349–2356.
32. Greene, S.J., Fonarow, G.C., Solomon, S.D., et al. Influence of atrial fibrillation on post-discharge natriuretic peptide trajectory and clinical outcomes among patients hospitalized for heart failure: insights from the ASTRONAUT trial. Eur J Heart Fail 19 (2017), 552–562.
33. Löfman, I., Szummer, K., Dahlström, U., Jernberg, T., Lund, L.H., Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid-range, and reduced ejection fraction. Eur J Heart Fail, 2017 Mar 29 [E-pub ahead of print].
34. Abdul-Rahim, A.H., Perez, A.C., MacIsaac, R.L., et al. Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials. Eur Heart J 38 (2017), 742–750.
35. Kotecha, D., Holmes, J., Krum, H., et al. Efficacy of beta blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet 384 (2014), 2235–2243.